Wegovy side effects: every rate on the FDA label
Most common adverse reactions (incidence ≥5%) in adults or pediatric patients aged 12 years and older are: nausea, diarrhea, vomiting, constipation, abdominal pain, dysesthesia, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, gastroesophageal reflux disease, and hair loss. (6.1) dailymed.nlm.nih.gov, Sep 27, 2026
Wegovy injection
Boxed warning
WARNING: RISK OF THYROID C-CELL TUMORS
dailymed.nlm.nih.gov, Sep 27, 2026In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures.
dailymed.nlm.nih.gov, Sep 27, 2026
| Side effect | Placebo | 2.4 mg |
|---|---|---|
| Nausea | 16% | 44% |
| Diarrhea | 16% | 30% |
| Vomiting | 6% | 24% |
| Constipation | 11% | 24% |
| Abdominal Pain | 10% | 20% |
| Headache | 10% | 14% |
| Fatigue | 5% | 11% |
| Dyspepsia | 3% | 9% |
| Dizziness | 4% | 8% |
| Eructation | <1% | 7% |
| Hair Loss | 1% | 3% |
Percent of people in the trial who reported it. Placebo is the comparison group.
| Side effect | Placebo | 2.4 mg | 7.2 mg |
|---|---|---|---|
| Nausea | 13% | 35% | 39% |
| Vomiting | 6% | 16% | 22% |
| Dysesthesia | 0% | 6% | 22% |
| Constipation | 8% | 19% | 20% |
| Abdominal pain | 7% | 9% | 12% |
| Fatigue | 5% | 9% | 11% |
| Headache | 7% | 8% | 9% |
| Dizziness | 1% | 5% | 6% |
| Hair loss | 1% | 3% | 6% |
Percent of people in the trial who reported it. Placebo is the comparison group.
In clinical trials in adults for weight reduction, 1.4% of WEGOVY-treated patients and 1% of patients receiving placebo experienced injection site reactions (including injection site pruritus, erythema, inflammation, induration, and irritation).
dailymed.nlm.nih.gov, Sep 27, 2026
Who stopped because of side effects
- 2.4 mg: 6.8% vs 3.2% placebo stopped for adverse reactions.
In these clinical trials, 6.8% of patients treated with 2.4 mg WEGOVY injection and 3.2% of patients treated with placebo permanently discontinued treatment as a result of adverse reactions.
dailymed.nlm.nih.gov, Sep 27, 2026 - 7.2 mg: 5% (7.2 mg), 5% (2.4 mg), 2% placebo stopped for adverse reactions.
In these clinical trials, 5% of patients treated with 7.2 mg WEGOVY injection, 5% of patients treated with 2.4 mg of WEGOVY injection and 2% of patients treated with placebo permanently discontinued treatment as a result of adverse reactions.
dailymed.nlm.nih.gov, Sep 27, 2026
Who should not take it, pregnancy and breastfeeding
- Contraindicated with personal/family history of MTC or MEN 2.
a personal or family history of MTC or in patients with MEN 2 [see Warnings and Precautions (5.1)].
dailymed.nlm.nih.gov, Sep 27, 2026 - Contraindicated after a prior serious hypersensitivity reaction to semaglutide or excipients.
a prior serious hypersensitivity reaction to semaglutide or to any of the excipients in WEGOVY injection or WEGOVY tablet. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with WEGOVY [see Warnings and Precautions (5.7)].
dailymed.nlm.nih.gov, Sep 27, 2026 - Pregnancy: stop Wegovy used for weight reduction when pregnancy is recognized.
Weight loss offers no benefit to a pregnant patient and may cause fetal harm. When a pregnancy is recognized, advise the pregnant patient of the risk to a fetus. Discontinue WEGOVY in pregnant patients who are using it for weight reduction
dailymed.nlm.nih.gov, Sep 27, 2026 - Stop at least 2 months before a planned pregnancy.
discontinue WEGOVY in patients at least 2 months before they plan to become pregnant to account for the long half-life of semaglutide [see Use in Specific Populations (8.1)].
dailymed.nlm.nih.gov, Sep 27, 2026 - Injection: no data on subcutaneous semaglutide in human milk.
There are no data on the presence of subcutaneously administered semaglutide or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production.
dailymed.nlm.nih.gov, Sep 27, 2026
Label revised 6/2026: read the full label on DailyMed. The label lists more reactions and warnings than this page.
Wegovy tablets
Boxed warning
WARNING: RISK OF THYROID C-CELL TUMORS
dailymed.nlm.nih.gov, Sep 27, 2026In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures.
dailymed.nlm.nih.gov, Sep 27, 2026
- Tablet trial adverse reactions similar to injection Table 3.
In the clinical trial with WEGOVY 25 mg tablets, the types and frequency of common adverse reactions were similar to those listed in Table 3.
dailymed.nlm.nih.gov, Sep 27, 2026 - Tablets: dysesthesia 5% vs 0 placebo.
In a clinical trial with WEGOVY 25 mg tablets, 5% of WEGOVY-treated patients and no placebo-treated patients reported dysesthesia adverse reactions.
dailymed.nlm.nih.gov, Sep 27, 2026 - Tablets: severe GI adverse reactions 2% vs 0% placebo.
Severe gastrointestinal adverse reactions were reported in 2% of WEGOVY tablet-treated and 0% of placebo-treated patients, respectively.
dailymed.nlm.nih.gov, Sep 27, 2026
Who stopped because of side effects
- Section 6.1: 6.9% (25 mg tablets) vs 5.9% placebo stopped for adverse reactions.
In the clinical trial, 6.9% of patients treated with WEGOVY 25 mg tablets and 5.9% patients treated with placebo permanently discontinued treatment as a result of adverse reactions.
dailymed.nlm.nih.gov, Sep 27, 2026 - Section 14.2 gives 6.8% (not 6.9%) for the same comparison; the label is internally inconsistent.
Adverse reactions led to treatment discontinuation in 6.8% of patients treated with WEGOVY 25 mg tablet and 5.9% patients receiving placebo.
dailymed.nlm.nih.gov, Sep 27, 2026
Who should not take it, pregnancy and breastfeeding
- Contraindicated with personal/family history of MTC or MEN 2.
a personal or family history of MTC or in patients with MEN 2 [see Warnings and Precautions (5.1)].
dailymed.nlm.nih.gov, Sep 27, 2026 - Contraindicated after a prior serious hypersensitivity reaction to semaglutide or excipients.
a prior serious hypersensitivity reaction to semaglutide or to any of the excipients in WEGOVY injection or WEGOVY tablet. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with WEGOVY [see Warnings and Precautions (5.7)].
dailymed.nlm.nih.gov, Sep 27, 2026 - Pregnancy: stop Wegovy used for weight reduction when pregnancy is recognized.
Weight loss offers no benefit to a pregnant patient and may cause fetal harm. When a pregnancy is recognized, advise the pregnant patient of the risk to a fetus. Discontinue WEGOVY in pregnant patients who are using it for weight reduction
dailymed.nlm.nih.gov, Sep 27, 2026 - Stop at least 2 months before a planned pregnancy.
discontinue WEGOVY in patients at least 2 months before they plan to become pregnant to account for the long half-life of semaglutide [see Use in Specific Populations (8.1)].
dailymed.nlm.nih.gov, Sep 27, 2026 - Tablets: breastfeeding not recommended (SNAC in human milk).
Lactation: Breastfeeding not recommended during treatment with WEGOVY tablets. (8.2)
dailymed.nlm.nih.gov, Sep 27, 2026 Because of the unknown potential for serious adverse reactions in the breastfed infant due to the possible accumulation of SNAC, and because there are alternative formulations of semaglutide that do not contain SNAC that can be used during lactation, advise patients that breastfeeding is not recommended during treatment with WEGOVY tablets.
dailymed.nlm.nih.gov, Sep 27, 2026
Label revised 6/2026: read the full label on DailyMed. The label lists more reactions and warnings than this page.
Doses and schedule: Wegovy dosing · Price: Wegovy cost · All medications: side effects compared
This page reports what the label says; it is not medical advice. Tell your prescriber about any side effect.Medical disclaimer.